UCLA Researchers & Innovators
Industry & Investors
News & Events
About
Concierge
Search Results - mutation
2
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Viral Vector-Based Gene Therapy for OPA1 Gene
Mutation
-Induced Dominant Optic Atrophy (UCLA Case No. 2025-004)
UCLA researchers in the Department of Ophthalmology have developed a viral vector-based gene therapy to restore OPA1 protein levels in patients with OPA1-mutated dominant optic atrophy. The optimized vectors will be delivered intravitreally to patients’ eyes, providing a minimally invasive, effective treatment with reduced side effects. BACKGROUND:...
Published: 3/6/2025
|
Inventor(s):
Xianjie Yang
Keywords(s):
Adeno-associated viruses (AAV)
,
disease model
,
dominant optic atrophy
,
Gene Therapy
,
intravitreal delivery
,
Lentivirus Viral Vector
,
mitochondria
,
mutation
,
Neuron
,
OPA1
,
Ophthalmology
,
pluripotent stem cell (PSC)
,
retinal ganglion cell
Category(s):
Therapeutics > CNS and Neurology
,
Therapeutics > Gene Therapy And Editing
,
Therapeutics > Ophthalmology
CHST6 Mini Gene - CHST6 Expression Construct With Native Promoter (UCLA Case No. 2023-301)
UCLA researchers from the Department of Human Genetics and Department of Ophthalmology have developed a mini gene encoding a protein which is mutated in macular corneal dystrophy, leading to a potential gene therapy for this disorder. BACKGROUND: Macular corneal dystrophy (MCD) is a rare genetic disease caused by
mutation
s in the CHST6 gene, which...
Published: 2/14/2025
|
Inventor(s):
Wenlin Zhang
,
Anthony Aldave
Keywords(s):
AAV
,
Adeno-associated viruses (AAV)
,
Gene Editing Systems
,
Gene Therapy
,
genetics
,
keratinocytes
,
macular corneal dystrophy
,
mini gene
,
mutation
,
native promoter
,
Ophthalmology
Category(s):
Therapeutics > Ophthalmology
,
Therapeutics > Gene Therapy And Editing